DOCSLIB.ORG

Molecular Radiotherapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Radiotherapy CME Nuclear medicine Clinical Medicine 2012, Vol 12, No 4: 381–6 demanding specialist skills. A recent review in haemophilia-related post-haemorrhage Molecular radiotherapy of molecular radiotherapy across the UK synovitis of the knees and ankles.8 showed that whilst the administration of I-131 is fairly widespread, the use of new From pain relief to extending life therapeutic radiopharmaceuticals is lim- John Buscombe, consultant in nuclear ited primarily to a few centres in the South- Radiotherapy is an important treatment medicine, Department of Nuclear Medicine, East and North-West of England.1 Access to option for metastatic bone pain palliation. Addenbrooke’s Hospital, Cambridge treatment is, therefore, constrained both by Local field external beam radiotherapy is Shaunak Navalkissoor, consultant in drug availability and by the small number highly effective in patients with relatively nuclear medicine, Department of Nuclear of specialists with the appropriate knowl- limited skeletal metastases. Disseminated, Medicine, Royal Free Hospital, London edge and experience to undertake this type painful bone metastases following hor- of therapy. mone or chemotherapy failure can be better managed using hemibody radiation or sys- Over the past 10 years the term ‘molecular temic bone-seeking radionuclides. The imaging’ has become increasing familiar, Benign disease treatment advantages of the radionuclide approach and often (mis)used as a code for positron Radioiodine are excellent, with selective bone targeting emission tomography (PET). In some and low incidence of side effects. senses this is correct as PET exploits Although often considered as a treatment Patients are selected on the basis of bone increased uptake of a molecule designed to for cancer, radionuclide therapies are fre- scintigraphy demonstrating increased target a specific tissue whether by a physi- quently used to manage benign disease. uptake at sites of accelerated bone turnover ological process or secondary to pathology. The most common therapeutic application in the bone surrounding the metastases. Nuclear medicine was originally con- in the UK is radioiodine (I-131) treatment The target cell is not the tumour cell itself ceived as a therapeutic specialty, not prima- of hyperthyroidism and non-toxic goitre. but the surrounding fibroblasts and oste- rily for imaging. The role of molecular I-131 is highly effective, safe and probably oblasts which produce the pain mediators radiotherapy has changed since the first the most cost-efficient available treatment such as substance P and slow releasing patients were exposed to therapeutic for hyperthyroidism.2-4 Some patients and substance.9 unsealed sources of radioisotopes referrers may be concerned about potential 70–80 years ago, using simple isotopes such adverse effects of radioactivity, but these Radionuclides for pain relief as radiophosphorous (P-32) or radioiodine reservations can usually be dealt with by (I-131). Since then, complex treatments appropriate discussion and education. A The different radionuclides used for bone have been developed such as radioimmu- lack of knowledge and inertia from refer- pain palliation offer distinct physical prop- notherapy for non-Hodgkin’s lymphoma rers would seem to present the more serious erties such as half-life duration and emitted (NHL) or Y-90 selective internal radio- impediments to increasing the number of radioactivity path length, which in turn therapy (SIRT) for liver metastasis. patients treated. influence clinical response. Treatment with P-32 and I-131 are still Samarium-153 (Sm-153) lexidronate, for available, although the use of the former Radiation synovectomy example, has a relatively short half-life and for polycythaemia is now limited. I-131 less penetrating beta particle emission than remains widely used to treat both benign Radiation synovectomy is commonly per- the major alternative, the calcium analogue and malignant thyroid disease and has formed in Germany, but offered by only a strontium-89 (Sr-89). Sm-153 lexidronate become routine for the former. They have few centres in the UK. It can provide treatment relieves pain rapidly and rarely the advantage of being inexpensive, require important, durable benefit in patients with leads to significant myelosuppression, a relatively straightforward infrastructure significant mono-arthropathies. Treatment although repeated injections at three or four for safe delivery and are administered regu- is administered by intra-articular radiop- month intervals may be required for sus- larly in many UK centres. Other treatments harmaceutical injection, usually under tained benefit. By comparison, pain relief such as radiation synovectomy or radi- radiological or ultrasonographic guid- may be delayed for two to four weeks after opeptide therapy of neuroendocrine ance.5–7 Several different radionuclide Sr-89 administration. Bone marrow recovery tumours (NETs) require specific expertise agents are available, the choice governed by may be slow, but symptom response dura- and are less widely available. the size of the joint being treated. Low- tion is prolonged and may exceed six months There is good evidence that molecular energy beta particle-emitting agents are following a single injection.10–12 radiotherapies are well tolerated, associated used for the small joints of the hands and These treatments can be co-administered with limited side effects and can improve feet, for example, whereas high-energy, with other systemic treatments for bone both quality of life and survival. long range beta-emitting isotopes are better pain such as bisphosphonates or chemo- The recent development of other radio- suited to large joints such as the knee. therapy,13,14 although the latter is associ- nuclide therapies has led to increased cost, Radiosynovectomy is particularly effective ated with a higher incidence of bone requiring dedicated inpatient facilities and in reducing pain and increasing movement marrow suppression. © Royal College of Physicians, 2012. All rights reserved. 381 CCMJ1204-CME_381-386-Buscombe.inddMJ1204-CME_381-386-Buscombe.indd 338181 77/18/12/18/12 111:12:101:12:10 AAMM CME Nuclear Medicine Radium-223 somatostatin analogues which attach to the radiotherapy. The chimeric monoclonal type 2 receptor subtype (Fig 1). antibody rituximab has antitumour activity A new approach involves the use of low via targeting of the CD20 antigen expressed activity, bone-seeking alpha-emitting radi- Octreotide derivatives on mature lymphocytes and B cell tumours. onuclides given repeatedly at four-week This epitope is not present on precursor intervals to allow bone marrow recovery. In Many academic institutions have developed cells in the bone marrow so, after clearance phase II clinical trials, radium-223 (Ra- therapeutic radiopeptides using modified of CD20 cells (including tumour sites) 223) improved symptoms, reduced bone octreotide derivatives. The most promising, immunocompetent lymphocytes repopu- alkaline phosphatase and increased overall octreotate, can be linked via a chelator to late rapidly.39–40 15 survival compared with placebo. A phase beta particle-emitting isotopes such as lute- Anti-CD20 antibodies have been labelled III trial of Ra-223 versus placebo in over tium-177 (Lu-177) or yttrium-90 (Y-90) for with I-131 (I-131 tositumomab) and Y-90 900 men with prostate cancer reported a use in metastatic NETs. The results in over (ibritumomab tiuxetan). The latter is avail- 14-month median overall survival in the 1,500 patients, reported by a number of able in Europe and has been shown to Ra-223 treated group compared with centres around Europe, consistently show double the response rate to rituximab. 16 11 months on placebo. disease stability/overall response in about Treatment is administered by intravenous 70% of patients23–38 (Table 1). Disease stabi- infusion on an outpatient basis and is well 41,42 Networks to treat lisation appears to translate to prolonged tolerated. Y-90 ibritumomab tiuxetan neuroendocrine tumours median overall survival which may extend consolidation treatment following induc- beyond five years. Most centres observed tion chemotherapy prolonged progression- An expanding role of molecular radio- that patients who fail to show significant free survival by a factor of three in patients therapy has involved the palliative treat- radiological response immediately after with advanced follicular NHL.43 It has been ment of patients with disseminated NETs. therapy may demonstrate a late response, included safely in conditioning regimens Despite their low incidence, these tumours with tumour shrinkage up to one year after for autologous bone marrow transplanta- progress slowly such that the prevalence of the last treatment.35 tion in aggressive NHL, in combination NETs among patients attending a gastroin- To date, the promise of this treatment with myeloablative BEAM (BCNU, etopo- testinal tumour clinic approaches 10%.17 approach has been restricted by the paucity side, cytarabine and melphalan) chemo- Many of these tumours are hypersecretory, of RCT data. A multicentre phase III study therapy.44 leading to intractable symptoms such as of Lu-177-labelled DOTATATE is planned the carcinoid syndrome. Despite this slow in 2012–2013 which, it is hoped, will pro- The double whammy in liver growth NETs paradoxically often present vide the infrastructure and evidence base to tumours late with disseminated disease that cannot support future use. be managed surgically and are typically There is increasing
Load more

Recommended publications
  • Endo4 PRINT.Indb
    Contents 1 Tumours of the pituitary gland 11 Spindle epithelial tumour with thymus-like differentiation 123 WHO classifi cation of tumours of the pituitary 12 Intrathyroid thymic carcinoma 125 Introduction 13 Paraganglioma and mesenchymal / stromal tumours 127 Pituitary adenoma 14 Paraganglioma 127 Somatotroph adenoma 19 Peripheral nerve sheath tumours 128 Lactotroph adenoma 24 Benign vascular tumours 129 Thyrotroph adenoma 28 Angiosarcoma 129 Corticotroph adenoma 30 Smooth muscle tumours 132 Gonadotroph adenoma 34 Solitary fi brous tumour 133 Null cell adenoma 37 Haematolymphoid tumours 135 Plurihormonal and double adenomas 39 Langerhans cell histiocytosis 135 Pituitary carcinoma 41 Rosai–Dorfman disease 136 Pituitary blastoma 45 Follicular dendritic cell sarcoma 136 Craniopharyngioma 46 Primary thyroid lymphoma 137 Neuronal and paraneuronal tumours 48 Germ cell tumours 139 Gangliocytoma and mixed gangliocytoma–adenoma 48 Secondary tumours 142 Neurocytoma 49 Paraganglioma 50 3 Tumours of the parathyroid glands 145 Neuroblastoma 51 WHO classifi cation of tumours of the parathyroid glands 146 Tumours of the posterior pituitary 52 TNM staging of tumours of the parathyroid glands 146 Mesenchymal and stromal tumours 55 Parathyroid carcinoma 147 Meningioma 55 Parathyroid adenoma 153 Schwannoma 56 Secondary, mesenchymal and other tumours 159 Chordoma 57 Haemangiopericytoma / Solitary fi brous tumour 58 4 Tumours of the adrenal cortex 161 Haematolymphoid tumours 60 WHO classifi cation of tumours of the adrenal cortex 162 Germ cell tumours 61 TNM classifi
    [Show full text]
  • California Tumor Tissue Registry
    CALIFORNIA TUMOR TISSUE REGISTRY California Tumor Tissue Registry c/o: Department ofPathol ogy and Human Anatomy Lorna Linda University School ofMedicine 11021 Campus Avenue, AH 335 Loma Linda, Cnllfomin 92350 (909) 824-4788 FAX: (909) 478-4188 Target audience: Practicing pathologists and pathology residen.ts. Goal: To acquaint the participant with the histologic features of a variety of benign and malignant neoplasms and tumor-like conditions. Oblectlve: The participant will be able to recognize morphologic features of a variety of benign and malignant neoplasms and tumor-like conditions and relate those processes to pertinent references in the medical literature. Educational methods and media: Review of representative glass slides with associated histories. Feedback on consensus diagnoses from participating pathologists. Listing of selected references from the medical literature. Principal faculty: Weldon K. Bullock, MD Donald R. Chase, MD CME Credit: The CTTR designates this activity for up to 2 hours of continuing medical education. Participants must return their diagnoses to the CTTR as documentation of participation in this activity. Accreditation: The California Tumor Tissue Registry is accredited by the California Medical Association as a provider of continuing medical education. CONTRIBUTOR: Shelley L. Tepper, M.D. CASE NO. 1 • JANUARY 1997 San Francisco, CA TISSUE FROM: Thyroid ACCESSION #25451 CLINICAL ABSTRACf: This 34"year-old gay Caucasian male with generalized lymphadenopathy presented with a left neck mass. A few weeks later, a right neck mass developed. A total thyroidectomy was performed. GROSS PATHOLOGY: The right lobe of this 48 gram total thyroidectomy specimen vias markedly larger than the left and measured 7.0 x 3.0 x 4.0 em in greatest dimension.
    [Show full text]
  • Evaluation of Head and Neck Masses in Adults
    Evaluation of Head and Neck Masses in Adults Kristi Chang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery University of Iowa Hospitals and Clinics Annual Refresher Course for the Family Physician April 2018 1 Objectives Recognize when practitioners should worry about head and neck adenopathy Identify what are common serious causes of cervical lymphadenopathy and neck masses Understand how location of a neck mass guides differential diagnosis Identify indications warranting a biopsy of a neck mass and referral to an otolaryngologist 2 Neck mass –Background Definition: abnormal lesion that is visible, palpable, or seen on imaging study – can be acquired or congenital Location: – below mandible, above clavicle, deep to skin Etiologies can be varied – Adult neck masses are more likely to be malignant neoplasms – Persistent neck masses should be considered malignant until proven otherwise 3 Neck Mass - History What is the Age of patient? • Adults > 40 yrs old ~ 80% of neck masses are neoplastic (except thyroid) • Peds neck masses ~ 80% infectious/inflammatory • 16-40 yrs ~ 30% neoplastic, 50% infectious/inflammatory What is the DURATION of the mass? What is the LOCATION of mass? Duration and location are key factors in developing differential diagnosis Any new, persistent lateral neck mass in an adult > 40 yrs old is likely to be malignant Many upper aerodigestive tract cancers present with the chief concern of a painless neck mass 4 Neck Mass - Duration impacts Etiology • Traumatic: hematoma, vascular injury • Infectious/Inflammatory: • adenopathy from viral or bacterial infection . ACUTE : onset over days • odontogenic . more likely to be symptomatic • salivary gland • Neoplastic process more likely: • metastatic from upper aerodigestive • tract mucosa .
    [Show full text]
  • Case Report: Primary Thyroid Lymphoma Presenting As a Rapidly Enlarging Thyroid Mass
    Endocrinology & Metabolism International Journal Case Report Open Access Case report: primary thyroid lymphoma presenting as a rapidly enlarging thyroid mass Abstract Volume 1 Issue 1 - 2014 Primary thyroid lymphoma is a rarely encountered clinical entity that occurs mainly in G Papadakis,1 A Tertipi,1 M Papazian,2 K elderly females. We present a case of B-cell origin thyroid lymphoma. The diagnosis was 1 1 made by combined histology and immunochemistry. A 79-year-old woman presented with Moustakas, A Pappas 1Department of Endocrinology and Diabetes Center, Metaxa an enlarging neck mass with compression signs, dysphagia and pressure sensation around Anticancer Hospital, Greece the neck. On admission, the sonogram of the thyroid gland showed an enlarged mass and 2Department of Pathology, Metaxa Anticancer Hospital, Greece CT scan demonstrated diffuse enlargement of the thyroid extending on the anterior chest wall. After total thyroidectomy, the histological investigation revealed the presence of a Correspondence: Georgios Papadakis, Department of diffuse large B-cell non-Hodgkin’s lymphoma without other loci from the systemic staging. Endocrinology and Diabetes Center, Metaxa Anticancer The patient underwent chemotherapy and radiation therapy. Clinicians should include Hospital, Mpotasi 51, Pireaus 18537, Athens, Greece, Tel primary thyroid lymphoma in the differential diagnosis of a rapidly enlarging thyroid mass. 00306932598392, Email Keywords: primary thyroid lymphoma, non-hodgkin lymphoma, thyroid cancer Received: October 21, 2014 | Published: November 15, 2014 Abbreviations: PTL, primary thyroid lymphomas; MALT, On admission three months later, the symptoms deteriorated. mucosa associated lymphoid tissue Clinical examination revealed a firm, immobile and painless mass descending in the anterior chest wall.
    [Show full text]
  • THYROID CANCER STRUCTURED REPORTING PROTOCOL (2Nd Edition 2020)
    THYROID CANCER STRUCTURED REPORTING PROTOCOL (2nd Edition 2020) Incorporating the: International Collaboration on Cancer Reporting (ICCR) Carcinoma of the Thyroid Dataset www.ICCR-Cancer.org Core Document versions: • ICCR dataset: Carcinoma of the Thyroid 1st edition v1.0 • AJCC Cancer Staging Manual 8th edition • World Health Organization (2017) Classification of Tumours of Endocrine Organs (4th edition). Volume 10 2 Structured Reporting Protocol for Thyroid Cancer 2nd edition ISBN: 978-1-76081-423-6 Publications number (SHPN): (CI) 200280 Online copyright © RCPA 2020 This work (Protocol) is copyright. You may download, display, print and reproduce the Protocol for your personal, non-commercial use or use within your organisation subject to the following terms and conditions: 1. The Protocol may not be copied, reproduced, communicated or displayed, in whole or in part, for profit or commercial gain. 2. Any copy, reproduction or communication must include this RCPA copyright notice in full. 3. With the exception of Chapter 6 - the checklist, no changes may be made to the wording of the Protocol including any Standards, Guidelines, commentary, tables or diagrams. Excerpts from the Protocol may be used in support of the checklist. References and acknowledgments must be maintained in any reproduction or copy in full or part of the Protocol. 4. In regard to Chapter 6 of the Protocol - the checklist: • The wording of the Standards may not be altered in any way and must be included as part of the checklist. • Guidelines are optional and those which are deemed not applicable may be removed. • Numbering of Standards and Guidelines must be retained in the checklist, but can be reduced in size, moved to the end of the checklist item or greyed out or other means to minimise the visual impact.
    [Show full text]
  • Coexistence of Diffuse Large B-Cell Lymphoma and Papillary Thyroid
    case report Coexistence of diffuse large B-cell lymphoma and papillary thyroid carcinoma in a patient affected by Hashimoto’s thyroiditis 1 Maria Trovato1,2, Giuseppe Giuffrida1, Antonino Seminara3, Simone Fogliani4, Department of Clinical and Experimental Medicine, Unit 2 1 5 Vittorio Cavallari , Rosaria Maddalena Ruggeri , Alfredo Campennì of Endocrinology, University of Messina, Messina, Italy 2 Department of Human Pathology, University of SUMMARY Messina, Messina, Italy 3 Azienda Sanitaria Provinciale, Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. On the contrary, Messina, Italy primary thyroid lymphoma (PTL) is a rare disease, accounting for 2% to 5% of all thyroid malignancies. 4 Unit of Radiology, Hospital Despite several cases in which both PTC and PTL arise in the setting of Hashimoto’s thyroiditis (HT), of Milazzo, Messina, Italy the coexistence of both tumors in HT patients is very rare. Herein we report the case of a 66-year-old 5 Department of Biomedical woman with long-standing nodular HT under replacement therapy, who presented with a fast, painless Sciences and Morphological and Functional Images, Unit of enlargement in the right anterior side of the neck. Thyroid ultrasonography demonstrated increased Nuclear Medicine, University growth of a hypoechoic nodule in the right lobe measuring 32 x 20 mm. A total thyroidectomy was of Messina, Messina, Italy performed, and histology revealed a diffuse large B-cell lymphoma (DLBCL) on a background of florid HT. Moreover, a unifocal papillary microcarcinoma, classical variant (7 mm, pT1aNxMx), was Correspondence to: discovered. The patient was then treated with chemotherapy for the PTL, but she did not undergo Rosaria Maddalena Ruggeri radioactive iodine ablation treatment for the microPTC as per guidelines.
    [Show full text]
  • Lymphoma Involving the Mediastinum Challenges in Diagnosis
    Lethal tracheal dissolution during treatment for thyroid lymphoma 1121 Figure 2 Portable chest radiograph after intubation to mention whether the tumour invaded the showing extensive trachea or larynx.4 In one report two patients subcutaneous emphysema demonstrated obstructive symptoms and bi- of the upper chest and opsy proven tracheal invasion by thyroid Thorax: first published as 10.1136/thx.50.10.1121 on 1 October 1995. Downloaded from neck. The cervical trachea is markedly distended lymphoma; both patients received chemo- (arrows). therapy with resolution ofobstruction and with- out tracheal perforation, and both were alive one and two years later without evidence of disease.5 Computed tomographic scanning is the re- commended method of assessment of extra- thyroid extension of lymphoma.' Early awareness of tracheal involvement by lymph- oma should alert the clinician to the remote possibility of tracheal dissolution during treat- ment of this extremely difficult clinical prob- lem. mon: hoarseness (9-67%), dysphagia (9-60%), 1 Randall J, Obeid ML, Blackledge GR. Haemorrhage and perforation of gastrointestinal neoplasms during chemo- and dyspnoea or stridor (9-35%).5 Although therapy. Ann R Coil Surg Engl 1986;68:286-9. the optimal treatment for thyroid lymphoma 2 Shaw JHF, Holden A, Sage M. Thyroid lymphoma. Br J Surg 1989;76:895-7. is uncertain, patients with stage IIE or more 3 Tupchong L, Hughes F, Harmer CL. Primary lymphoma of advanced disease should probably receive the thyroid: clinical features, prognostic factors, and results oftreatment. IntjRadiat OncolBiolPhys 1986;12:1813-21. chemotherapy in addition to local treatment 4 HamburgerJI, MillerJM, Kini SR.
    [Show full text]
  • ABSITE Review – January 2011
    American Board of Surgery In- Training Exam ABSITE - 2011 Matt Landman (With lots of material borrowed from Bailey and Forbes) January 7, 2011 “Never memorize what you can look up in books” ABSITE Review – January 2011 • January 7 – Endocrine surgery – Surgical principles – Hepatobiliary & Transplant surgery – Surgical oncology • January 14 – Practice questions • January 21 – Thoracic surgery – Vascular Surgery – Surgical Critical Care and Trauma – Head & Neck – Peds Surgery • January 28 – High Yield ABSITE Topics • January 29 - ABSITE How It’s Broken Down? • 220 questions • Junior level (PGY 1 & 2) Exam • 60% Basic Science • 40% Clinical Management • Senior Level (> PGY 3) Exam • 20% Basic Science • 80% Clinical Management Break down . Content Category Junior Level Senior Level Body as a whole (General Surgery and 67% 25% Surgical Critical Care) GI Tract 10% 25% CV/Respiratory 7.8% 16.7% GU, Head/Neck, Skin, MS, 7.8% 16.7% CNS Endocrine, Spleen, 7.8% 16.7% Lymphoma, Breast Endocrine surgery Endocrine • Asymptomatic Adrenal Mass • Rule out pheochromocytoma before biopsy • Surgery is indicated if: • > 4-6cm • Functioning • Enlarging • Breast cancer most common metastases to adrenal gland. Endocrine • Adrenal insufficiency • #1 cause is withdrawal of exogenous steroids • Cushing syndrome • Diagnosis: 1. 24-hour urine cortisol 2. Low dose dexamethasone suppression test 3. Measure ACTH 4. If serum ACTH high—high dose dexamethasone suppression test • Etiology: 1. Pituitary adenoma 2. Ectopic ACTH (small cell lung CA) 3. Adrenal adenoma Endocrine
    [Show full text]
  • BAES Guidelines on Training and Management of Endocrine Disease
    GUIDELINES FOR THE SURGICAL MANAGEMENT OF ENDOCRINE DISEASE AND TRAINING REQUIREMENTS FOR ENDOCRINE SURGERY THE BRITISH ASSOCIATION OF ENDOCRINE SURGEONS CONTENTS 1 GUIDELINES 3 2 SURGICAL TREATMENT OF DISEASES OF THE THYROID GLAND 2.1 MANAGEMENT OF PATIENTS WITH NODULAR GOITRE 4 2.2 THYROID MALIGNANCY 5 Follicular Cancer 6 Medullary Thyroid Cancer (MTC) 7 Thyroid Lymphoma 8 2.3 ANAPLASTIC THYROID CANCER 8 2.4 THYROTOXICOSIS 9 3 SURGICAL TREATMENT OF THE PARATHYROID GLANDS 3.1 PRIMARY HYPERPARATHYROIDISM 10 3.2 RENAL HYPERPARATHYROIDISIM (Secondary or Tertiary Hyperparathyroidism) 11 4 SURGICAL TREATMENT OF DISEASES OF THE ADRENAL GLAND Investigations 12 Cushings Syndrome 12 Primary Hyperaldosteronism - Adrenocortical Adenoma- Conn’s Syndrome 12 Phaeochromocytoma 12 Incidentaloma 12 Adrenocortical Carcinoma 13 5 SURGICAL TREATMENT OF THE ENDOCRINE PANCREAS 5.1 INSULINOMA 14 5.2 GASTRINOMA (Zollinger-Ellison Syndrome) 14 6 PATIENT INFORMATION SHEETS 6.1 THYROIDECTOMY FOR BENIGN NODULAR DISEASE OF THE THYROID 17 6.2 THYROTOXICOSIS (Overactive Thyroid) 19 6.3 ADVICE TO PATIENTS LEAVING HOSPITAL AFTER ADMINISTRATION OF 131-IODINE 21 6.4 RENAL HYPARATHYROIDISM (RHPT) 22 6.5 PRIMARY HYPERPARATHYROIDISM (HPT) 24 APPENDIX 1 - TRAINING REQUIREMENTS AND CURRICULUM FOR ENDOCRINE SURGERY Requirements for Training in Endocrine Surgery 26 Basic Science Curriculum 26 Clinical Curriculum 27 Index Cases 28 To be a General Surgeon with an interest in Endocrine Surgery 28 To be a Sub-Specialist in Endocrine Surgery 28 2 Guidelines for the Surgical Management of Endocrine Disease GUIDELINES The British Association of Endocrine Surgeons (BAES) is the representative body of British surgeons who have a special interest in the surgery of the endocrine glands other than the pituitary.
    [Show full text]
  • Original Article Concomitant Papillary Thyroid Carcinoma and Mucosa-Associated Lymphoid Tissue Thyroid Lymphoma in the Setting of Hashimoto Thyroiditis
    Int J Clin Exp Pathol 2018;11(6):3076-3083 www.ijcep.com /ISSN:1936-2625/IJCEP0075602 Original Article Concomitant papillary thyroid carcinoma and mucosa-associated lymphoid tissue thyroid lymphoma in the setting of Hashimoto thyroiditis Xia-Bin Lan1*, Jun Cao1*, Xu-Hang Zhu1*, Zhe Han2, Yu-Qing Huang1,4, Ming-Hua Ge1, Hai-Yan Yang3 Departments of 1Head and Neck Surgery, 2Medical Imaging, 3Lymphoma, Zhejiang Cancer Hospital, Gongshu District, Hangzhou 310022, China; 4Zhejiang Chinese Medical University, Hangzhou, China. *Equal contributors. Received March 7, 2018; Accepted April 13, 2018; Epub June 1, 2018; Published June 15, 2018 Abstract: The simultaneous occurrence of papillary thyroid carcinoma (PTC) and mucosa-associated lymphoid tis- sue (MALT) lymphoma of the thyroid gland is extremely rare, and many questions about their diagnosis and treat- ment remain unsolved. We report three cases of patients with both PTC and MALT thyroid lymphoma in the setting of Hashimoto thyroiditis (HT). Patient characteristics, pre-operative examination, histological findings, treatments, and follow-up were reviewed. In addition, we searched PubMed, Embase, and ISI Web of Science databases for articles published in the English language using the key words “lymphoma” and “thyroid”, and we reviewed almost all the reports about simultaneous occurrence of PTC and MALT thyroid lymphoma. In conclusion, PTC and MALT thyroid lymphoma can exist concomitantly, especially in patients with longstanding HT. These rare cases highlight the importance of close communication between clinicians, histopathologists, and radiologists to ensure that such rare cases are not missed; a multidisciplinary approach and careful surveillance are also needed. Keywords: Papillary thyroid carcinoma, lymphoma, hashimoto thyroiditis, treatment Introduction have been reported in the literature [4-9], diag- nosis and treatment of patients with PTC and Papillary thyroid carcinoma (PTC) is the most MALT thyroid lymphoma is unclear.
    [Show full text]
  • Primary Lymphoma of Thyroid: a Diagnostic Dilemma
    Case Report Open Access J Surg Volume 2 Issue 2 - February 2017 Copyright © All rights are reserved by Namita Bhutani Primary Lymphoma of Thyroid: A Diagnostic Dilemma Rajnish Kalra1, Monika Sangwan1, Namita Bhutani1, Sunita Singh1 and Ramesh Lamba2 1Depertment of Pathology, PGIMS Rohtak, India 2Depertment of Surgery, PGIMS Rohtak, India Submission: February 07, 2017; Published: February 14, 2017 *Corresponding author: Namita Bhutani, Department of Pathology, PGIMS Rohtak, Kailash Hills, New Delhi, India, (110065), Tel: ; Fax: +91-1262-211308; Email: Abstract Primary Lymphoma of Thyroid is a rarely encountered clinical entity that occurs in late age intrinsically associated with Hashimotos thyroiditis, comprising of 0.6 to 5 per cent of thyroid cancers in most series. We present a case of B-cell origin thyroid lymphoma. The diagnosis was made by combined histology and immunochemistry. A 60-year-old woman presented with an enlarging neck mass with odynophagia. On admission, the sonogram of the thyroid gland showed an enlarged mass and CT scan demonstrated diffuse enlargement of the thyroid. The histological investigation revealed the presence of a diffuse large B-cell non-Hodgkin’s lymphoma. The patient underwent chemotherapy. Clinicians should include primary thyroid lymphoma in the differential diagnosis of a rapidly enlarging thyroid mass. Thyroid ultrasound and of lymphoma. The prognosis is generally excellent but can be varied because of the heterogeneous nature of thyroid lymphomas. Despite its rarity,fine needle PTL shouldaspiration be promptly cytology, recognizedusing flow cytometrybecause its and management Immunohistochemistry, is quite different remain from the the main treatment modalities of other used neoplasms to confirm of the the presence thyroid gland.
    [Show full text]
  • Usefulness of Core Needle Biopsy for the Diagnosis of Thyroid Burkitt's
    Bernardi et al. BMC Endocrine Disorders (2018) 18:86 https://doi.org/10.1186/s12902-018-0312-9 CASE REPORT Open Access Usefulness of core needle biopsy for the diagnosis of thyroid Burkitt’s lymphoma: a case report and review of the literature Stella Bernardi1,2* , Andrea Michelli1, Deborah Bonazza1,3, Veronica Calabrò2, Fabrizio Zanconati1,3, Gabriele Pozzato1,4 and Bruno Fabris1,2 Abstract Background: Thyroid lymphomas are an exceptional finding in patients with thyroid nodules. Burkitt’s lymphoma is one of the rarest and most aggressive forms of thyroid lymphomas, and its prognosis depends on the earliness of medical treatment. Given the rarity of this disease, making a prompt diagnosis can be challenging. For instance, fine-needle aspiration (FNA) cytology, which is the first-line diagnostic test that is performed in patients with thyroid nodules, is often not diagnostic in cases of thyroid lymphomas, with subsequent delay of the start of therapy. Case presentation: Here we report the case of a 52-year-old woman presenting with a rapidly enlarging thyroid mass. Thyroid ultrasonography demonstrated a solid hypoechoic nodule. FNA cytology was only suggestive of a lymphoproliferative disorder and did not provide a definitive diagnosis. It is core needle biopsy (CNB) that helped us to overcome the limitations of routine FNA cytology, showing the presence of thyroid Burkitt’s lymphoma. Subsequent staging demonstrated bone marrow involvement. The early start of an intensive multi-agent chemotherapy resulted in complete disease remission. At 60 months after the diagnosis, the patient is alive and has not had any recurrence. Conclusions: Clinicians should be aware that thyroid Burkitt’s lymphoma is an aggressive disease that needs to be treated with multi-agent chemotherapy as soon as possible.
    [Show full text]